Dhaval K. Shah, PhD, named top reviewer for Journal of Pharmaceutical Sciences

Shah was one of only 27 top reviewers worldwide. Individuals deemed as experts in their fields are invited by the journal to review.

“Peer review is a cornerstone of science and critical to the publication of our journal,” says Robert Dawdy, assistant editor for the journal. “[Shah’s] thoughtful comments and critiques have improved our authors’ research.”

Shah's research is focused on the development and evaluation of biologically-based therapies, including monoclonal antibodies, bispecific antibodies and antibody‐drug conjugates (ADCs) for the treatment of cancer and metabolic, eye and central nervous system diseases.

His work has led to improved discovery and development of ADCs, especially their preclinical‐to‐clinical translation. Shah has also established the first multiscale systems pharmacokinetic-pharmacodynamic model for ADCs, which is widely‐used in academia and the pharmaceutical industry.

He has performed several pioneering investigations, including developing the first brain microdialysis system for antibodies, inventing the biodistribution coefficient concept, and establishing a platform physiologically-based pharmacokinetic model and quantitative structure‐pharmacokinetic relationships for biologics.

It is Shah’s first year as a reviewer for the journal.

“This work helps us maintain the quality of research that is being done and being published in the field of pharmaceutical sciences, by providing expert opinion on the quality of experiments being done, data being generated, and analysis being done on the data,” Shah says.

The Journal of Pharmaceutical Sciences is a monthly peer-reviewed scientific journal published by Elsevier on behalf of the American Pharmacists Association, with the support of the International Pharmaceutical Federation.